Article Sidebar
Views pdf: 0
EVALUATION OF THE TREATMENT OUTCOMES OF SECUKINUMAB IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS AT NGHE AN GENERAL FRIENDSHIP HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis. Subjects and Methods: A controlled interventional study was conducted on 62 patients with moderate-to-severe plaque psoriasis, including 31 patients treated with secukinumab and 31 patients treated with conventional therapies. Efficacy was assessed using PASI and DLQI scores at baseline, week 4, and week 16. Adverse events were monitored throughout the treatment period. Results: At baseline, mean PASI scores were comparable between the two groups (29.41 ± 4.10 vs. 29.16 ± 4.79; p = 0.826). After 4 weeks, mean PASI in the secukinumab group decreased to 7.04 ± 2.11 compared with 17.50 ± 4.12 in the conventional group (p = 0.000); 71% of patients in the secukinumab group achieved PASI 75, while none did in the conventional group. After 16 weeks, mean PASI was 1.96 ± 1.43 in the secukinumab group versus 8.96 ± 1.95 in the conventional group (p = 0.000); all patients in the secukinumab group achieved PASI 75 and 67.7% achieved PASI 90, compared with 38.7% and 0% in the conventional group. DLQI improved significantly: 1.26 ± 0.89 in the secukinumab group versus 7.45 ± 2.11 in the conventional group (p = 0.000). Reported adverse events were mostly mild, including 3 cases of latent tuberculosis (9.6%) and 1 case of mild pruritus (3.2%). Conclusions: Secukinumab demonstrated superior efficacy and safety compared with conventional therapies, providing rapid improvement in skin lesions and quality of life in patients with moderate-to-severe plaque psoriasis
Article Details
Keywords
Plaque psoriasis; secukinumab; PASI; DLQI.
References
2. Langley R, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren R, et al. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2022;188(2):198–207.
3. Ortiz-Salvador JM, Saneleuterio-Temporal M, Magdaleno-Tapial J, Velasco-Pastor M, Pujol-Marco C, Sahuquillo-Torralba A, et al. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. J Am Acad Dermatol. 2019;81(2):427-432.
4. Augustin M, Jullien D, Martin A, Peralta C. Real-world evidence of secukinumab in psoriasis treatment – a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2019;33:819-827.
5. Nguyen HT, Pham NTU, Tran TNA, Nguyen NTT, Vu TTP. Secukinumab demonstrated high effectiveness in Vietnamese patients with moderate-to-severe plaque psoriasis in a real-world clinical setting: 16-week results from an observational study. Dermatol Ther. 2021;11(4):1613-1621.
6. Bissonnette R, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate to severe psoriasis through 5 years of treatment. J Eur Acad Dermatol Venereol. 2018;
7. Gottlieb AB, Deodhar A, McInnes IB, Baraliakos X, Reich K, Schreiber S, et al. Long-term safety of secukinumab across three indications: an integrated pooled clinical trial and post-marketing surveillance data. Acta Derm Venereol. 2022; 102:adv00698.
8. Langley R, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren R, et al. Secukinumab maintains efficacy and safety in moderate-to-severe plaque psoriasis through to year 5, with most patients relapsing but response is rapidly recaptured upon reinitiation of treatment. J Am Acad Dermatol. 2022;86(3):429-439.